iRhythm Technologies, Inc. — Form 10-Q Summary
Period: Three months ended March 31, 2023; filed May 4, 2023. The filing identifies the registrant as iRhythm Technologies, Inc. (Nasdaq: IRTC); the request metadata says iRhythm Holdings, Inc.
Business context
iRhythm provides remote cardiac monitoring services through its Zio wearable systems and associated data-analysis and reporting platform. Revenue is primarily from U.S. third-party payors, including commercial insurers and Medicare, with a smaller contribution from healthcare institutions. The company reports that substantially all revenue was generated in the United States.
Key financial results
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $111.4 million | $92.4 million |
| Gross profit / margin | $75.7 million / 68% | $61.8 million / 67% |
| Operating expenses | $115.2 million | $110.3 million |
| Operating loss | $39.5 million | $48.5 million |
| Net loss | $39.1 million; $1.29 per share | $50.6 million; $1.71 per share |
| Adjusted EBITDA, non-GAAP | Loss of $12.0 million | Loss of $4.8 million |
| Cash used in operations | $30.8 million | $38.9 million |
Revenue increased 21%, mainly from higher service volume and improved CMS reimbursement, partly offset by lower net average selling prices and increased contractual allowances. Gross margin improved one percentage point as higher volumes lowered fixed cost per unit, despite higher material and freight costs. SG&A rose 37% to $100.3 million, reflecting higher payroll and stock compensation, $5.7 million of transformation costs, and increases in travel, professional services, marketing and bad-debt expense. Net loss improved year over year, but adjusted EBITDA loss widened; the prior-year comparison included $26.6 million of impairment and restructuring charges.
Financial position and liquidity
- At March 31, cash and cash equivalents were $52.8 million and short-term investments were $123.5 million, totaling $176.3 million; accounts receivable was $49.6 million.
- Cash and cash equivalents declined $26.0 million during the quarter. Investing activities provided $3.8 million, including investment maturities, while capital expenditures were $8.4 million, including $6.2 million of capitalized internal-use software.
- Debt was $34.9 million net of issuance costs (about $35.0 million principal). No revolving loans were outstanding; $8.4 million of letters of credit were in use. The company said $40.0 million of additional term-loan capacity and $16.6 million of revolving availability remained.
- The term loan bears a floating rate and begins scheduled principal repayments in April 2025, with maturity in March 2027. The company reported covenant compliance at quarter-end and continued access to its facilities following SVB’s closure and transfer of its deposits and loans to First-Citizens.
- Management said existing liquidity, available facilities and expected service revenue should meet requirements for the foreseeable future and that liquidity was adequate for the next 12 months. This is management’s assessment, not a guarantee.
Changes, outlook and material matters
- CMS accounted for 24% of Q1 revenue, compared with 22% a year earlier. New 2023 national Medicare rates for relevant long-term Holter codes were $243.65 and $231.79; the filing warns rates may change and notes potential commercial-payor pricing effects.
- Transformation expenses were $5.7 million in Q1. The company expects further costs through mid-2024, with restructuring activities substantially complete by then; it anticipates administrative efficiencies after completion. No specific full-year revenue or earnings guidance is provided in the supplied filing text.
- R&D increased 41%, including investment in software, the Zio Monitor platform and future technology. The company expects R&D and cost of revenue to increase in absolute dollars as it expands and develops offerings.
- The company received a new DOJ Consumer Protection Branch subpoena on April 4, 2023, seeking documents about its products and services; it is cooperating and cannot predict the scope or outcome. A securities class action dismissal is on appeal. No loss estimate is provided for these matters.
- The FDA classified a Zio AT labeling correction as a Class II recall; the company said it completed customer notification and requested closure on March 31, 2023. The recall database status remained open in the filing, and FDA communications continued.
- Risks include Medicare and commercial reimbursement changes, claim denials and collection delays, revenue-cycle transformation execution, dependence on single-source components and semiconductor availability, capacity constraints, competition, and regulatory compliance. The company also cites inflation, higher interest rates and broader economic uncertainty.
- Q1 2023 had no impairment or restructuring charges, versus $26.6 million in Q1 2022. The company recorded $18.3 million of stock-based compensation, a significant non-cash expense. It also reported executive changes, including the COO’s March 2023 resignation.
Most important facts for investors to verify
- Whether revenue growth, CMS reimbursement and service volumes continue to offset lower average selling prices and rising contractual allowances.
- Whether receivables convert to cash as expected, and whether the revenue-cycle transformation improves collections without disrupting claims or service delivery.
- Cash burn, remaining borrowing availability, floating-rate debt costs and ongoing covenant compliance.
- Developments in the DOJ subpoenas, securities litigation appeal and FDA Class II recall status.
- Whether transformation spending, SG&A growth and stock-based compensation moderate while the company pursues growth and product investment.